Genmab — Oktober 2024
-
translating this https://medical.nikkeibp.co.jp/leaf/all/cancernavi/news/202410/586322.html gave some results , best in english- During the median follow-up period of 13.7 months, the median OS was 15.0 months (95% CI: 9.7-NE) in the TV group and 8.5 months (95% CI: 6.8-10.6)
-
Bryder mit hoved med Gen1046 completion data, og vil gerne tro på at datoen er udsat fordi patienterne lever længere end de oprindeligt havde regnet med. Men det kan vel også have at gøre med deres mitigation plan, som nu tilsiger at visse patienter skal have pauser for a ikke udmatte T-cellerne. Det sidste er også nyt ift den oprindelige plan og kunne sagtens være grundet til den udsatte dato uden at være negativt.
-
ja jeg vile jo gerne høre " due to patients staying much longer on the trial then first expected, we now longer expect to complete the stude by... ... . det kunne aktiekursen godt bruge
Men de besværer sig jo heller ikke med at informere markedet når der igangsættes phase 3 forsøg, så sådan en lille detalje som en dato skal vi nok ikke regne med at høre om. -
AbbVie Q3 2024 Epkinly US $16, Intern. $27, Total $43 U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories. https://news.abbvie.com/2024-10-30-AbbVie-Reports-Third-Quarter-2024-Financial-Results
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind